GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale

What is it about?

Obesity may be successfully treated with analogs of the hormone GLP-1 , but recent developments have shown that antagonism of the other incretin hormone, GIP, may be helpful. Here, we summarize the physiologic, genetic, and clinical evidence for pursuing GIPR antagonism. Preclinical studies have supported this and a phase-1 study in humans have provided proof-of principle.

Featured Image